• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    LENZ Therapeutics, Inc. - Common Stock (NQ: LENZ )

    24.22 +0.13 (+0.54%)
    Streaming Delayed Price Updated: 12:52 PM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 21,220
    Open 24.17
    Bid (Size) 24.15 (1)
    Ask (Size) 24.29 (2)
    Prev. Close 24.09
    Today's Range 24.07 - 24.64
    52wk Range 14.42 - 24.84
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    +49.51%
    +49.51%
    1 Month
    +36.91%
    +36.91%
    3 Month
    +46.79%
    +46.79%
    6 Month
    +49.51%
    +49.51%
    1 Year
    +49.51%
    +49.51%

    More News

    Read More
    ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From LENZ Therapeutics, Inc.
    Via GlobeNewswire
    LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
    From Lenz Therapeutics, Inc.
    Via GlobeNewswire
    Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
    Via Benzinga
    Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
    Via Benzinga
    LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
    From LENZ Therapeutics, Inc.
    Via Business Wire
    LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
    From LENZ Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.